Clinical significance of miR-3178 in non-small cell lung cancer patients
miR-3178 in NSCLC: Clinical Significance
Sažetak
Background & objectives：Non-small cell lung cancer (NSCLC) is a malignant tumor with high morbidity and mortality, with low survival rate and poor prognosis This study aims to explore the diagnostic and prognostic value of miR-3178 in NSCLC.
Methods: Study included 118 NSCLC patients and 97 healthy subjects. RT-qPCR measured miR-3178 and MIB2 in serum or cell lines. χ2 tests linked miR-3178 to clinicopathological features. ROC, Kaplan-Meier, and Cox analyses evaluated diagnostic and prognostic significance of miR-3178 and MIB2.
Results: Compared to the control group, the expression level of miR-3178 was significantly reduced, while MIB2 expression was notably elevated in NSCLC patients. The expression of miR-3178 is significantly correlated with the TNM stage and LNM in NSCLC patients. NSCLC patients with higher miR-3178 expression levels exhibit significantly higher 5-year overall survival rates. Furthermore, TNM stage, miR-3178 expression, and MIB2 expression are independent risk factors that influence the prognosis of NSCLC. MIB2 serves as a target gene of miR-3178, and their expression levels display a significant negative correlation. When diagnosing NSCLC solely based on miR-3178, the AUC is 0.838; for MIB2 alone, the AUC is 0.818; however, when miR-3178 and MIB2 are combined for diagnosis, the AUC increases to 0.903.
Conclusion: The downregulation of miR-3178 and upregulation of MIB2 are associated with the progression and deterioration of NSCLC patients, indicating poor prognosis. miR-3178 targets MIB2, and their combined diagnosis can enhance the diagnostic value for NSCLC, potentially reducing the risk of adverse outcomes.
Sva prava zadržana (c) 2026 Haizhen Yu, Shizhen Li
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.